Open Monoclonal Technology Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Open Monoclonal Technology Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11475
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Open Monoclonal Technology Inc (OMT), a subsidiary of Ligand Pharmaceuticals Inc, is a biotechnology company that discovers and develops human monoclonal antibody platform based on transgenic rats. The company provides products such as omnirat, omnimouse and omniflic. Its omnirat is an antibody platform that generates human monoclonal antibodies based on transgenic rats. OMT’s omnimouse is a transgenic mouse that complements omnirat and expands epitope coverage. The company’s omniflic is the rat engineered with a fixed light chain for discovery of bi-specific, fully human antibodies. It serves pharmaceutical and biotech companies. The company offers alternative to generating and characterizing human antibody development candidates. OMT is headquartered in San Diego, California, the US.

Open Monoclonal Technology Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Symphogen Enters Into Agreement With Open Monoclonal Technology 11
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 12
Open Monoclonal Expands Agreement with CNA Development 13
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 14
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 15
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 16
WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 17
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 18
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 19
Licensing Agreements 20
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 21
Open Monoclonal Enters into Licensing Agreement with Celgene 22
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 23
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 24
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 25
Open Monoclonal Enters into Licensing Agreement with Amgen 26
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 27
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 28
Acquisition 29
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 29
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology’s Spin-Out Companies 30
Open Monoclonal Technology Inc – Key Competitors 31
Open Monoclonal Technology Inc – Key Employees 32
Open Monoclonal Technology Inc – Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Key Facts 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Open Monoclonal Technology Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Symphogen Enters Into Agreement With Open Monoclonal Technology 11
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 12
Open Monoclonal Expands Agreement with CNA Development 13
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 14
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 15
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 16
WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 17
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 18
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 19
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 21
Open Monoclonal Enters into Licensing Agreement with Celgene 22
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 23
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 24
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 25
Open Monoclonal Enters into Licensing Agreement with Amgen 26
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 27
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 28
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 29
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 30
Open Monoclonal Technology Inc, Key Competitors 31
Open Monoclonal Technology Inc, Key Employees 32

List of Figures
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Open Monoclonal Technology Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • mixi, Inc.:企業の戦略・SWOT・財務分析
    mixi, Inc. - Strategy, SWOT and Corporate Finance Report Summary mixi, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Fugro NV (FUR):石油・ガス:M&Aディール及び事業提携情報
    Summary Fugro NV (Fugro) is an integrated provider of geotechnical, survey, subsea and geosciences services. The company specializes in earth and engineering data services, from project preparation through to data acquisition, processing, analysis and interpretation, reporting and consulting. It ass …
  • Canpotex Ltd:企業の戦略的SWOT分析
    Canpotex Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Cooper Tire & Rubber Company:企業の戦略・SWOT・財務情報
    Cooper Tire & Rubber Company - Strategy, SWOT and Corporate Finance Report Summary Cooper Tire & Rubber Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Hill’s Pet Nutrition, Inc.:企業の戦略的SWOT分析
    Hill's Pet Nutrition, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Andhra Bank (ANDHRABANK):企業の財務・戦略的SWOT分析
    Andhra Bank (ANDHRABANK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Depuy Synthes Companies:企業の戦略・SWOT・財務分析
    Depuy Synthes Companies - Strategy, SWOT and Corporate Finance Report Summary Depuy Synthes Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Bata India Limited
    Bata India Limited - Strategy, SWOT and Corporate Finance Report Summary Bata India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Ingles Markets Inc:企業の戦略・SWOT・財務分析
    Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report Summary Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Lycatel Services Ltd:企業の戦略的SWOT分析
    Lycatel Services Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Alimera Sciences Inc (ALIM):企業の財務・戦略的SWOT分析
    Alimera Sciences Inc (ALIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Nestle Health Science SA:医療機器:M&Aディール及び事業提携情報
    Summary Nestle Health Science SA (Nestle Health), a subsidiary of Nestle SA, is a health science company that manufactures nutritional and medicinal products derived from botanical plants. The company provides nutritional therapies for chronic conditions related to gastrointestinal diseases, aging p …
  • Hang Lung Properties Limited:企業の戦略・SWOT・財務情報
    Hang Lung Properties Limited - Strategy, SWOT and Corporate Finance Report Summary Hang Lung Properties Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • PQ Group Holdings Inc (PQG):企業の財務・戦略的SWOT分析
    PQ Group Holdings Inc (PQG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • MLM Biologics Inc:企業の製品パイプライン分析2018
    Summary MLM Biologics Inc (MLM Biologics) is a medical device company that provides optimum wound care management for patients and doctors. The company’s product includes bio-ConneKt Wound Matrix, a collagen-based wound dressing for chronic vascular ulcers, draining wounds, partial and full thicknes …
  • FDC Ltd (FDC):企業の財務・戦略的SWOT分析
    Summary FDC Ltd (FDC) is a pharmaceutical company that manufactures and markets of oral rehydration salts, ophthalmics and functional foods. The company also provides active pharmaceuticals ingredients (APIs). It provides products for the therapeutic segments of anti-infectives, gastrointestinals, o …
  • GQ Life Sciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary GQ Life Sciences Inc (GQ Life Sciences), formerly GenomeQuest Inc, a subsidiary of Aptean Inc, is a life science information and search company that offers genomic software to search patents for biological sequences. The company provides lifequest, a patent search tool that provides a soluti …
  • Ensco Plc (ESV):石油・ガス:M&Aディール及び事業提携情報
    Summary Ensco Plc (Ensco) is a provider of offshore drilling services to the global oil and gas industry. The company owns and operates fleet of drillships, semisubmersibles, moored semisubmersibles, premium jackups and deepwater managed units. It also provides drilling management services to custom …
  • Karoon Gas Australia Ltd (KAR):石油・ガス:M&Aディール及び事業提携情報
    Summary Karoon Gas Australia Ltd (Karoon) is a major independent upstream oil and gas company, which explores for oil and gas and develops assets. It also operates projects in Brazil and Peru. Karoon has significant drilling opportunities in proven and prospective petroleum systems. The company focu …
  • Crane Co:企業の戦略・SWOT・財務分析
    Crane Co - Strategy, SWOT and Corporate Finance Report Summary Crane Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆